The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe

Natalie Bohm (), Sarah Bermingham, Frank Grimsey Jones, Daniela C. Gonçalves-Bradley, Alex Diamantopoulos, Jessica R. Burton and Hamish Laing
Additional contact information
Natalie Bohm: Pfizer Limited
Sarah Bermingham: Symmetron Limited
Frank Grimsey Jones: Symmetron Limited
Daniela C. Gonçalves-Bradley: Symmetron Limited
Alex Diamantopoulos: Symmetron Limited
Jessica R. Burton: Pfizer Limited
Hamish Laing: Swansea University

PharmacoEconomics, 2022, vol. 40, issue 1, No 4, 13-29

Abstract: Abstract Objectives The aim was to outline the challenges of implementing outcomes-based contracts (OBCs) in Europe. Methods A scoping review was conducted, building on the searches of a previous systematic review and updating them for December 2017 until May 2021. The combined results were screened, based on inclusion and exclusion criteria. All identified studies published in the English language that described specific OBC schemes for medicines in European countries were included. Insights into the challenges of OBCs were extracted and analysed to develop a conceptual framework. Results Ten articles from the previous systematic review matched our inclusion criteria, along with 14 articles from electronic searches. Analysis of these 24 articles and classification of the challenges revealed that there are multiple barriers that must be overcome if OBCs that benefit all stakeholders are going to be adopted widely across Europe. These challenges were grouped according to five key themes: negotiation framework; outcomes; data; administration and implementation; and laws and regulation. Conclusions If the promise of OBCs is to be fully realised in Europe, there remain major challenges that need to be overcome by all stakeholders working in partnership. The overlapping and interconnected nature of these challenges highlights the complexity of OBC arrangements.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-021-01070-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:40:y:2022:i:1:d:10.1007_s40273-021-01070-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-021-01070-1

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().